The Silent Epidemic: Why Heart Disease Is the Biggest Threat Women Aren't Taking Seriously

Every year, heart disease kills more women than all cancers combined. It is not a man's disease. It never was. Yet the cultural narrative around cardiovascular disease (CVD) has been so thoroughly shaped by male-centric research and male-centric symptoms that millions of women — and their clinicians — are operating with an incomplete, and potentially dangerous, picture of risk.

This is not a minor gap in awareness. It is a systemic failure with measurable consequences.

According to a 2024 Journal of the American College of Cardiology (JACC) State-of-the-Art Review, only 56% of women know that cardiovascular disease is their number one health threat. Younger women show the lowest awareness of all — the very demographic that would benefit most from early intervention. Meanwhile, standard risk calculators routinely underestimate women's true cardiovascular risk, and women develop coronary heart disease approximately 10 years later than men — a delay that creates a false sense of security rather than a genuine biological advantage.

The result is a population of women who are under-screened, under-diagnosed, and under-treated for the condition most likely to kill them.

The Same Risk Factors, a Heavier Burden

Part of the problem is that even when traditional risk factors are identified in women, their significance is frequently underweighted. The data tells a different story.

Women with diabetes face a 44% greater risk of cardiovascular disease compared to men with diabetes. Female smokers carry a 25% higher risk of coronary artery disease than their male counterparts. Obesity confers a 64% increased risk of coronary artery disease in women — substantially higher than the equivalent risk in men. And hypertension, often dismissed as a manageable chronic condition, is the leading cause of heart failure in women, frequently presenting with characteristics that differ from the classic male presentation.

The clinical implication is clear: the same risk factor, in a female patient, demands a higher index of suspicion and a more aggressive response. Functional practitioners who apply a one-size-fits-all risk framework are systematically underserving their female patients.

The Risk Factors Medicine Has Been Ignoring

Beyond the traditional metrics lies a constellation of female-specific cardiovascular risk factors that standard clinical assessments rarely capture — yet each functions as an independent risk multiplier.

Adverse pregnancy outcomes are among the most underappreciated. Preeclampsia, gestational diabetes, preterm delivery before 37 weeks, small-for-gestational-age infants, and placental abruption are not merely obstetric events. They are early warning signals of underlying vascular and metabolic vulnerability — and the risk they confer persists for 30 to 46 years after delivery (Borrowman et al., JACC 2025). Pregnancy, in this framework, functions as a physiological stress test. When it reveals cracks in the cardiovascular system, those cracks do not simply heal when the pregnancy ends.

Polycystic Ovarian Syndrome (PCOS) elevates risk for metabolic syndrome, type 2 diabetes, and subsequent heart disease. Premature menopause — defined as cessation of ovarian function before age 40 — is strongly linked to higher rates of cardiovascular events later in life. Migraines with aura are associated with increased stroke risk. And chronic psychological stress and depression, which disproportionately affect women, function as major cardiovascular risk multipliers that are rarely incorporated into formal risk assessments.

Each of these factors, taken alone, would warrant clinical attention. Together, they represent a compounding burden that standard risk scores are simply not designed to capture.

Menopause: The Inflection Point

If there is a single biological transition that most dramatically reshapes a woman's cardiovascular trajectory, it is menopause. The loss of estrogen's protective vascular effects does not merely remove a benefit — it actively accelerates a cascade of harmful physiological changes.

A pooled analysis of 301,438 women (Zhu D, et al., Human Reproduction, 2020) quantified the relationship between age at menopause and cardiovascular risk with striking clarity. Women who experience premature menopause before age 40 carry a hazard ratio of 1.55 for cardiovascular events — meaning they are 55% more likely to experience a cardiovascular event than women who reach menopause at the expected time. Early menopause between ages 40 and 44 carries an HR of 1.30. Even relatively early menopause between 45 and 49 confers an HR of 1.12. Surgical menopause carries a 22% higher CVD risk than natural menopause.

The mechanisms driving this risk are multiple and interconnected. Estrogen normally promotes nitric oxide production and vascular dilation; its loss produces endothelial dysfunction that impairs blood flow response. LDL cholesterol rises while HDL falls, accelerating atherosclerosis. Body fat redistributes toward visceral adiposity, driving metabolic dysfunction and insulin resistance. Sympathetic nervous system tone increases, elevating blood pressure and heart rate. And chronic low-grade vascular inflammation drives ongoing plaque buildup.

Understanding these mechanisms is not merely academic. It allows clinicians to target interventions precisely — addressing each pathway rather than treating menopause as a single, monolithic event.

Autoimmune Disease: The Overlooked Cardiovascular Threat

Perhaps the most striking — and most clinically underappreciated — finding in women's cardiovascular medicine is the relationship between autoimmune disease and heart disease.

80% of autoimmune disease patients are women. And all 19 major autoimmune diseases are independently associated with increased cardiovascular risk. A landmark 2022 Lancet study by Conrad et al. found that women with autoimmune disease carry a hazard ratio of 3.59 for cardiovascular events — meaning they are more than three and a half times as likely to experience a cardiovascular event as women without autoimmune disease. Systemic lupus erythematosus (SLE) carries an HR of 2.82. Rheumatoid arthritis is associated with 50% increased cardiovascular mortality, based on a UK study of 22 million individuals (Mortensen et al., JACC 2024).

An HR of 2.82 is not a statistical footnote. It is a clinically actionable signal that justifies earlier and more frequent cardiovascular screening, aggressive management of modifiable risk factors, co-management with cardiology, and direct patient education about elevated risk. A woman with lupus who has never been told she is at nearly three times the cardiovascular risk of her peers has been failed by the system meant to protect her.

A New Framework for Women's Cardiovascular Care

Consider a 38-year-old woman who presents for a wellness evaluation. Her Framingham risk score is low. She appears healthy. But her history reveals preeclampsia during her first pregnancy, a diagnosis of PCOS, and a family history of early heart disease. Under a standard risk framework, she might be reassured and sent home. Under a sex-informed functional cardiology framework, she has at least three independent CVD risk multipliers — each of which persists and compounds over time.

This is the gap that must be closed.

Effective cardiovascular care for women requires a fundamentally different approach to risk assessment — one that incorporates adverse pregnancy history as a permanent entry in the cardiovascular risk profile, screens actively for autoimmune conditions, accounts for the timing and nature of menopause, and treats psychological stress and depression as cardiovascular risk factors rather than separate concerns.

It also requires a different approach to patient education. A woman who does not know that heart disease is her greatest health threat cannot advocate for herself. A clinician who does not know that her diabetes carries 44% more cardiovascular risk than her male patient's cannot advocate for her either.

The Takeaway

Heart disease does not discriminate. But medicine, for too long, has — by designing risk tools around male physiology, conducting research predominantly in male populations, and allowing female-specific risk factors to remain on the margins of clinical practice.

The evidence is now unambiguous. Women face a distinct cardiovascular risk profile, shaped by hormonal biology, reproductive history, autoimmune vulnerability, and psychosocial factors that standard assessments routinely miss. Closing this gap is not a matter of adding a few questions to an intake form. It requires a wholesale reorientation of how cardiovascular risk is understood, assessed, and communicated in women.

The first step is awareness — for clinicians and patients alike. Because the most dangerous heart disease is the one no one saw coming.

This post is based on the Functional Cardiology Review Sheet developed by Giovanni Campanile, MD, FACC. For clinical resources and continuing education, visit CorAeon.com.